Experimental Gene Therapy Restores Immune Function in Children
- This article details the long-term positive outcomes of gene therapy for Adenosine Deaminase-Severe Combined immunodeficiency (ADA-SCID), a rare and life-threatening genetic disorder.
- * The Therapy: The gene therapy involves collecting a child's blood stem cells, using a modified lentivirus to deliver a healthy copy of the ADA gene into those...
- In essence, the article highlights a highly effective and increasingly accessible gene therapy that offers a durable solution for children with ADA-SCID, considerably improving their quality of life.
summary of the Article: Gene Therapy for ADA-SCID Shows Long-Term Success
This article details the long-term positive outcomes of gene therapy for Adenosine Deaminase-Severe Combined immunodeficiency (ADA-SCID), a rare and life-threatening genetic disorder. Hear’s a breakdown of the key points:
* The Therapy: The gene therapy involves collecting a child’s blood stem cells, using a modified lentivirus to deliver a healthy copy of the ADA gene into those cells, and then reinfusing the corrected cells back into the patient. This allows the body to produce functional immune cells.
* Long-Term Results: A study published in the New England Journal of Medicine followed 59 patients treated between 2012 and 2019, with follow-up data spanning over a decade for some. Immune function remained stable in successfully treated patients, with no significant treatment-limiting complications.
* High Success Rate: The therapy was accomplished in all but three of the 62 cases, and those patients were able to return to standard treatments.
* Improved Accessibility: A key advancement is the successful use of frozen corrected stem cells. This allows for local stem cell collection and processing at specialized facilities, reducing the need for families to travel long distances for treatment. It also allows for more thorough testing and precise dosing.
* Safety Profile: Most adverse events were mild and related to preparatory procedures, not the gene therapy itself.
* Future Steps: The UCLA team is working towards FDA approval, with support from various organizations, and Rarity PBC is licensed to commercialize the therapy.
In essence, the article highlights a highly effective and increasingly accessible gene therapy that offers a durable solution for children with ADA-SCID, considerably improving their quality of life.